Clinical validation of a plasma-based antibody-free LC–MS method for identifying CSF amyloid positivity in mild cognitive impairment
This predictive model has demonstrated high accuracy for the identification of brain amyloid deposition in patients with MCI. Derived cutoffs enabled over 70% reduction in invasive testing, supporting efficient and cost-effective identification of candidates for DMTs.
Authors
- Noelia Fandos
- J. Terencio
- Jorge Loscos (ORCID: https://orcid.org/0000-0003-1435-1779)
- María Pascual‐Lucas (ORCID: https://orcid.org/0000-0002-4638-3153)
- Gerard Piñol‐Ripoll (ORCID: https://orcid.org/0000-0002-4495-2113)
- José Antonio Allué (ORCID: https://orcid.org/0000-0002-5690-3618)
- Ricardo Gonzalo
- Adrián Guzmán Sánchez (ORCID: https://orcid.org/0000-0003-1104-882X)
- Jordi A. Matías‐Guiu
- Leticia Sarasa
- Judith Romero
- Rubén Sabido-Vera
Institutions
- Hospital Clínico San Carlos (ES)
- Hospital Universitari de Santa Maria (ES)
- Grifols (Spain) (ES)
- Fundació Clínic per a la Recerca Biomèdica (ES)
Publication Details
- Journal
- Frontiers in Aging Neuroscience
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fnagi.2025.1681516
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Grifols